The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Continue reading at TechCrunch.
Enveda Secures $311M To Bring More Nature-Derived Ai Drugs Into Cli…
